AR018652A1 - Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores - Google Patents

Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores

Info

Publication number
AR018652A1
AR018652A1 ARP990102767A ARP990102767A AR018652A1 AR 018652 A1 AR018652 A1 AR 018652A1 AR P990102767 A ARP990102767 A AR P990102767A AR P990102767 A ARP990102767 A AR P990102767A AR 018652 A1 AR018652 A1 AR 018652A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
carbon
het
substituted
Prior art date
Application number
ARP990102767A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of AR018652A1 publication Critical patent/AR018652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Inhibidor de catepsina K del tipo pirrolidinona que tiene la formula (I), en la que: X se selecciona del grupo formado por oxígeno, azufre, SO y SO2;Y se selecciona del grupo formado por H2 y oxígeno; donde, si Y es H2, entonces el enlace - - - - representa dos enlaces sencillos y donde si Y es O,entones el enlace - - - - representa un enlace doble; R1 se selecciona del grupo formado por hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6,cicloalquilC3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, (CH2)0-6CO2R, y (CH2)0-6Ar; R11 se selecciona del grupo formado por hidrogeno, alquilo C1-6,alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; R2 se selecciona del grupo formado por H, alquilo C1-6,alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; R3 se selecciona del grupo formado por H, alquilo C1-6,alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; alquilo C1-6 se selecciona del grupo formado pormetilo, etilo, n-propilo, isopropilo, n-butilo, isobutilo, t-butilo, pentilo, n-pentilo, isopentilo, neopentilo y hexilo sustituidos o no sustituidos, ylos isomeros alifáticos de los mismos;cicloalquilo C3-6 se selecciona del grupo formado por ciclopropano, ciclobutano, ciclopentano, y ciclohexanosustituidos y no sustituidos; alquenilo C2-6 es un grupo alquilo C2-6, en el que se ha sustituido un enlace sencillo carbono-carbono por un dobleenlace carbono-carbono; alquinilo C2-6 es un grupo alquilo C2-6, en el que se ha sustituido un enlace sencillo carbono-carbono por un triple enlacecarbono-carbono; Ar se selecciona del grupo formado por fenilo o naftilo; o fenilo o naftilo sustituido con uno o más de Ph-alquilo C0-6, Het-alquiloC0-6, alcoxi C1-6, Ph-alcoxi C0-6, Het-alcoxi C0-6, OH, (CH2)0-6CO2R, donde R es como se ha definido anteriormente, (CH2)1-6NRR, O(CH2)1-6NRR; ofenilo o naftilo sustituido con 1-3 restos seleccionadosentre alquilo C1-4, OR, N(R)2, SR, CF3, NO2, CN, CO2R, CON(R), F, Cl, Br e I, o sustituido
ARP990102767A 1998-06-12 1999-06-10 Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores AR018652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8905698P 1998-06-12 1998-06-12

Publications (1)

Publication Number Publication Date
AR018652A1 true AR018652A1 (es) 2001-11-28

Family

ID=22215426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102767A AR018652A1 (es) 1998-06-12 1999-06-10 Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores

Country Status (10)

Country Link
EP (1) EP1086083A4 (es)
JP (1) JP2002517485A (es)
AR (1) AR018652A1 (es)
AU (1) AU4564499A (es)
CA (1) CA2334652A1 (es)
CO (1) CO5040090A1 (es)
DZ (1) DZ2815A1 (es)
MA (1) MA24877A1 (es)
PE (1) PE20000725A1 (es)
WO (1) WO1999064399A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034156A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
JP2003527429A (ja) 2000-03-21 2003-09-16 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
WO2002080920A1 (en) * 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
WO2003062192A1 (en) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74733A (en) * 1993-11-09 1997-02-28 Merck & Co Inc Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

Also Published As

Publication number Publication date
AU4564499A (en) 1999-12-30
MA24877A1 (fr) 1999-12-31
CA2334652A1 (en) 1999-12-16
WO1999064399A1 (en) 1999-12-16
JP2002517485A (ja) 2002-06-18
CO5040090A1 (es) 2001-05-29
EP1086083A1 (en) 2001-03-28
DZ2815A1 (fr) 2003-12-01
PE20000725A1 (es) 2000-09-28
EP1086083A4 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
AR041271A1 (es) Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
AR064731A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR064732A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
ECSP099600A (es) Co-cristales y composicón farmaceútica de los mismos
AR018186A1 (es) Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR016307A1 (es) Imidazopirimidinas e imidazopiridinas, metodo para el tratamiento de afecciones neurologicas, y composicion farmaceutica.
BR9509212A (pt) Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
AR020562A1 (es) Inhibidores de la sorbitol deshidrogenasa
BR0109588A (pt) Inibidores de caspase de carbamato e usos destes
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
AR018652A1 (es) Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores
AR076896A2 (es) Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados
AR050576A1 (es) Oxadiazolonas con actividad agonista de ppar-delta. composiciones farmaceuticas.
ATE546467T1 (de) Ortho-nitrosophenole als polymerisationshemmer
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
AR072510A1 (es) Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana
CO4820432A1 (es) Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina
AR055666A1 (es) Inhibidores inntr